Joost Beltman currently serves as the Associate Director of Planning for Global Third Party Manufacturers (TPMs) at Abbott, where he plays a pivotal role in orchestrating the forecasting process within the company’s Established Pharmaceuticals Division (EPD). With a robust background in pharmaceuticals, Joost brings a...
Joost Beltman currently serves as the Associate Director of Planning for Global Third Party Manufacturers (TPMs) at Abbott, where he plays a pivotal role in orchestrating the forecasting process within the company’s Established Pharmaceuticals Division (EPD). With a robust background in pharmaceuticals, Joost brings a wealth of expertise in supply chain management, particularly in production and demand planning, customer service, and distribution of solid, liquid, and sterile products. His leadership is characterized by a results-driven approach, ensuring that Abbott's manufacturing operations align seamlessly with market demands and regulatory requirements.
In his current role, Joost leads a dynamic team focused on optimizing the supply chain processes for third-party manufacturing partners. He is instrumental in implementing best practices in project planning and program management, leveraging his extensive knowledge of Good Manufacturing Practices (GMP) to uphold the highest quality standards. Joost’s ability to foster cross-functional collaboration is vital, as he works closely with procurement, quality assurance, and product launch teams to drive process improvements and enhance operational efficiency.
Key projects under Joost's leadership include the integration of advanced forecasting tools and the refinement of inventory management strategies, which have significantly reduced lead times and improved service levels. His proficiency in SAP products further enhances his capability to analyze data and make informed decisions that propel Abbott’s strategic objectives. As a highly motivated and creative team player, Joost is dedicated to delivering results that not only meet but exceed expectations, solidifying Abbott's position as a leader in the pharmaceutical industry.
